Clinical Trials · NCT01011751
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Takeda
- Enrollment
- 311
- Start date
- Apr 2004
- Locations
- 1 site, France
- Primary endpoint
- Percent Change from Randomization in Hot Flushes (HF) Score at Week 4 of Treatment